Kenneth Cartwright
Impact in
- Clinical Biochemistry top 0.5%
- Advanced Glycation End Products research
-
- Natural Antidiabetic Agents Studies
- Diabetes, Cardiovascular Risks, and Lipoproteins
Papers in
- Oncology 4
- Cancer Treatment and Pharmacology 4
-
- Advanced Glycation End Products research 4
- Co-authors
- Gary Dukart (4 shared papers)S Wolff (2 shared papers)Eli A. Friedman (2 shared papers)Peter G. Foiles (1 shared paper)Robert E. Ratner (1 shared paper)Frederick C. Whittier (1 shared paper)Barry I. Freedman (1 shared paper)Philip Raskin (1 shared paper)
- Journals
- Journal of Clinical Oncology (2 papers)Investigational New Drugs (2 papers)Controlled Clinical Trials (1 paper)Diabetes Research and Clinical Practice (1 paper)American Journal of Nephrology (1 paper)
- Partner nations
- United StatesIsraelCanada
In The Last Decade
Kenneth Cartwright
13 papers receiving 1.5k citations
Peers
Comparison fields: 5 of 86
- Clinical Biochemistry 556
- Endocrinology, Diabetes and Metabolism 371
- Nephrology 129
- Hematology 151
- Oncology 321
Countries citing papers authored by Kenneth Cartwright
This map shows the geographic impact of Kenneth Cartwright's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenneth Cartwright with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenneth Cartwright more than expected).
Fields of papers citing papers by Kenneth Cartwright
This network shows the impact of papers produced by Kenneth Cartwright. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenneth Cartwright. The network helps show where Kenneth Cartwright may publish in the future.
Co-authors
The 25 scholars most cited alongside Kenneth Cartwright, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2004 | 403 | |
| 2 | 1992 | 227 | |
| 3 | 1999 | 216 | |
| 4 | 1989 | 207 | |
| 5 | Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group. | 1990 | 154 |
| 6 | 1985 | 114 | |
| 7 | 1985 | 110 | |
| 8 | 1988 | 94 | |
| 9 | 1984 | 43 | |
| 10 | 1985 | 18 | |
| 11 | 2000 | 17 | |
| 12 | 1997 | 12 | |
| 13 | 2008 | 4 |
About Kenneth Cartwright
Kenneth Cartwright is a scholar working on Oncology, Clinical Biochemistry, Surgery, Molecular Biology and Cardiology and Cardiovascular Medicine, having authored 13 papers that have together received 1.6k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (4 papers), Advanced Glycation End Products research (4 papers), Chemotherapy-induced cardiotoxicity and mitigation (3 papers), Coenzyme Q10 studies and effects (2 papers), Muscle metabolism and nutrition (2 papers), Diabetes and associated disorders (2 papers), Mitochondrial Function and Pathology (2 papers) and Diabetes Treatment and Management (2 papers). The work is most often cited by research in Clinical Biochemistry (556 citations), Endocrinology, Diabetes and Metabolism (371 citations), Nephrology (129 citations), Hematology (151 citations) and Oncology (321 citations). Kenneth Cartwright has collaborated with scholars based in United States, Israel and Canada. Frequent co-authors include Gary Dukart, S Wolff, Eli A. Friedman, Peter G. Foiles, Robert E. Ratner, Frederick C. Whittier, Barry I. Freedman, Philip Raskin, Mark E. Williams and Sharon G. Adler. Their work appears in journals such as Journal of Clinical Oncology, Investigational New Drugs, Controlled Clinical Trials, Diabetes Research and Clinical Practice and American Journal of Nephrology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.